Senores Pharma: No IPO Fund Use Deviation for Q1 FY27

Senores Pharmaceuticals Limited has submitted its statement of deviation or variation in the utilization of funds raised through its Initial Public Offer (IPO) for the quarter ended June 30, 2026. The company confirms there has been no deviation from the objects stated in its prospectus dated December 24, 2024. The statement, reviewed by the Audit Committee and taken on record by the Board of Directors, indicates that while most funds were utilized as planned, minor unutilized amounts in certain categories were transferred to General Corporate Purposes (GCP) or other objectives as per board resolutions. Notably, there is an ongoing delay in deploying funds for setting up a manufacturing facility for sterile injections, for which shareholder approval for variation in objects and time extension is being sought.